Genhouse Pharma and XtalPi Announce Collaboration on Novel Small Molecule Anti-Cancer Drug Targeting Unmet Clinical Needs in Oncology

July 13, 2021, Suzhou, China—GEN HOUSE, a research and development enterprise dedicated to developing next-generation global anti-tumor small molecule drugs utilizing a combinatorial technology platform, announced today that it has entered into a project collaboration with AI drug discovery company XtalPi. The two parties will jointly develop first-in-class small molecule drugs (First-in-class) targeting novel targets for the treatment of malignant tumors. The collaboration focuses on unmet clinical needs in the field of malignant tumors and is expected to deliver more advanced clinical treatment solutions for malignant tumor therapy.

The collaboration between GEN HOUSE and XtalPi represents a powerful synergy between an advanced translational medicine technology platform and a cutting-edge AI-driven drug discovery platform. Leveraging its integrated technology platform, the GEN HOUSE team has accumulated extensive expertise in target validation and disease mechanism research, enabling in-depth investigation of fundamental biological mechanisms. XtalPi combines its AI drug discovery platform and high-precision computational chemistry tools with high-throughput medicinal chemistry experiments to conduct molecular design, evaluation, and experimental synthesis. Through continuous iteration, this process yields novel molecules with outstanding comprehensive profiles—including exceptional potency, selectivity, druggability, and safety—featuring innovative scaffolds and robust intellectual property protection. This partnership will focus on novel targets to develop the next generation of global First-in-class small-molecule anti-tumor drugs.

Unmet clinical needs are driving the original innovation of anti-tumor drugs in China. Developing high-quality novel anti-tumor drugs that offer excellent safety, superior patient treatment experiences, and improved quality of life is the shared goal of pharmaceutical R&D enterprises. GEN HOUSE and XtalPi jointly aspire to expand treatment options for patients through continuous technological innovation and integration, enabling them to access high-quality, affordable, safe, and effective novel anti-tumor drugs.

Dr. Wang Kuifeng, Founder and CEO of GEN HOUSE, said:

“The collaboration with XtalPi, a global leader in AI-driven drug discovery, is undoubtedly another encouraging milestone for GEN HOUSE. Dedicated to conquering ‘undruggable’ targets and prioritizing original innovation, we consistently monitor and actively embrace cutting-edge technologies to address unmet clinical needs. We are confident that by synergizing with XtalPi’s intelligent drug discovery platform and continuing to leverage our strengths in structural biology and translational medicine research, we will deliver newer, broader, and superior therapeutic options to cancer patients worldwide.”

XtalPi Co-founder and CEO Dr. Ma Jian said:

“The development of anti-cancer drugs holds profound social value and represents a significant technological challenge for the entire biopharmaceutical industry. The emergence of new technologies such as AI presents a valuable opportunity to substantially improve the R&D efficiency and success rate of oncology drugs, accelerating the process of bringing novel anti-cancer therapeutics to market. We are delighted to partner with GEN HOUSE, a biopharmaceutical company dedicated to the development of innovative oncology drugs. By integrating our complementary technological strengths, we aim to bring high-quality anti-cancer therapies to market.”

Executive Editor: Liuli

Disclaimer: This article is reprinted from Yaozhi Network. The copyright belongs to the original author. It is intended solely for informational purposes and does not represent the views of this platform. Should you have any concerns regarding the content, copyright, or other issues, please contact us by leaving a message on this website, and we will promptly remove the content!